Sources of Impurities in Pharmaceutical Substances

If you've ever sat in an out-of-specification investigation meeting, you've probably watched the conversation default almost immediately to "check the API supplier." It's an understandable reflex — but it's also frequently wrong, and that reflex is precisely why so many impurity investigations run longer than they should. An unexpected peak in a chromatogram can originate from a dozen genuinely different points across a product's entire lifecycle, from the very first reagent charged into a reactor to the printing ink on the box the finished tablets ship in.

Understanding the full landscape of where impurities actually come from — not just the most commonly blamed sources — is what separates a fast, correctly targeted root-cause investigation from a slow, expensive one that keeps looking in the wrong place. This article maps the complete source of impurity in pharmaceutical chemistry, organizes those sources into the categories that ICH Q3A/Q3B and related guidance actually use, and lays out the analytical and control strategy each category demands.

What Counts as a Pharmaceutical Impurity?

Before mapping sources, it's worth being precise about the definition itself, since "impurity" gets used loosely in casual lab conversation.

A pharmaceutical impurity is any component of a drug substance or drug product that is not the chemical entity defined as the active ingredient — encompassing organic impurities (process- and degradation-related), inorganic impurities (elemental and reagent-derived), and residual solvents, as formally categorized under ICH Q3A (impurities in new drug substances) and ICH Q3B (impurities in new drug products).

It answers one specific question: What is present in this material besides the substance it's supposed to be?

That framing matters because it makes clear that impurity control isn't a single test or a single supplier relationship — it's a lifecycle-spanning discipline that has to account for every point at which something other than the intended active substance could plausibly enter the material.

The Two Broad Categories: Process-Related vs. Product-Related Impurities

Nearly every specific source discussed in this article falls into one of two broad categories, and this distinction is the first and most important sorting mechanism for any investigation.

Process-related impurities arise during manufacturing — synthesis of the drug substance, or formulation of the drug product — and reflect something about how the material was made: unreacted starting material, a synthetic by-product, a reagent residue, a cross-contaminant from shared equipment.

Product-related (degradation) impurities arise after manufacturing is complete, through chemical or physical instability of the drug substance or drug product itself under the influence of heat, light, moisture, oxygen, or pH — reflecting something about the molecule's inherent stability rather than the manufacturing process.

This distinction drives fundamentally different investigation and control strategies: a process-related impurity is addressed by changing the synthetic route, purification, or manufacturing conditions, while a product-related impurity is addressed through formulation design, packaging selection, and storage condition control. Misclassifying which category an unexpected impurity belongs to is one of the most common ways an investigation gets sent down the wrong path entirely.

Source Category 1: Starting Materials and Raw Materials

The earliest possible entry point for impurities is, unsurprisingly, the very first materials charged into a synthesis or formulation process.

What goes wrong at this stage:

• Impurities inherent to the starting material's own manufacturing process — a starting material is itself a chemical product with its own impurity profile, and any impurity not adequately removed during its own purification can carry forward
• Batch-to-batch variability in starting material quality, particularly for materials sourced from multiple suppliers or manufactured via different synthetic routes at different sites
• Isomeric or structurally related contaminants present in the starting material that survive downstream synthetic steps because they behave chemically similarly to the intended reactant
• Excipients carrying trace contaminants from their own production, such as residual nitrite in certain grades of croscarmellose sodium or povidone — a well-documented contributor to nitrosamine formation risk in finished drug products

Why this source matters:

Because starting material impurities enter at the very beginning of a multi-step process, they have the maximum opportunity to persist, transform, or accumulate through every subsequent step. ICH Q11 explicitly requires justification of starting material quality and control strategy precisely because problems introduced this early are often the hardest and most expensive to trace and correct later in the process.

Source Category 2: Reagents, Solvents, and Catalysts

Every synthetic step introduces materials beyond the substrate itself — reagents that drive the reaction, solvents that dissolve and transport the reaction mixture, and catalysts that accelerate specific transformations. Each is a distinct potential impurity source.

What goes wrong at this stage:

• Incomplete reagent consumption, leaving unreacted reagent or its by-products in the reaction mixture
• Reagent-derived side reactions, generating structurally related but unintended products alongside the desired transformation
• Residual solvents persisting through inadequate drying or purification, governed quantitatively by ICH Q3C's class-based permitted daily exposure limits
• Catalyst and metal residues, particularly from transition-metal-catalysed coupling reactions increasingly common in modern API synthesis, governed by ICH Q3D elemental impurity limits
• Trace nitrite contamination in reagents and solvents — often present at levels the manufacturer never deliberately introduced or even tested for — which, in the presence of a vulnerable amine-bearing substrate, can drive nitrosamine formation regardless of whether sodium nitrite was ever used as a deliberate reagent

Why this source matters:

This category is where a substantial share of genotoxic and elemental impurity risk originates, and it is also the category most directly addressable through route-of-synthesis redesign — reagent substitution, catalyst selection, and solvent choice are all levers available to process chemists specifically because this impurity source sits within the manufacturer's own synthetic design decisions.

Source Category 3: Synthetic Intermediates and By-Products

As a multi-step synthesis proceeds, each reaction step generates not only the intended intermediate but, almost inevitably, some quantity of unintended by-product alongside it.

What goes wrong at this stage:

• Incomplete reactions, leaving residual starting material or partially reacted intermediate in the product stream
• Side reactions at reactive functional groups, generating structurally related impurities that closely resemble the intended intermediate and can be genuinely difficult to separate chromatographically
• Over-reaction or over-substitution, particularly at nucleophilic or electrophilic centres present in multiple positions on a molecule
• Dimerisation and oligomerisation, where two molecules of a reactive intermediate combine rather than each reacting independently with the intended coupling partner — a well-documented pathway across several drug classes, including certain statins
• Inadequate purification between synthetic steps, allowing an impurity generated at an early stage to carry forward, unnoticed, into subsequent steps where it may itself react further into a new, structurally distinct impurity

Why this source matters:

Because advanced intermediates are structurally closest to the final API, impurities generated at this stage are the ones most likely to survive final purification and appear in the released drug substance. ICH Q7's principle of progressively increasing GMP control as synthesis approaches the final API step exists precisely because this is where impurity risk concentrates most heavily.

Source Category 4: Manufacturing Equipment and Facility Environment

Impurities don't only come from the chemicals deliberately added to a process — the equipment and environment the process runs in can themselves be a source.

What goes wrong at this stage:

• Cross-contamination from shared equipment, where residues from a previous, unrelated product or process persist on reactor surfaces, gaskets, transfer lines, or filters despite cleaning procedures
• Equipment corrosion and leaching, introducing trace elemental impurities (iron, nickel, chromium) from stainless steel reactors, particularly under acidic or oxidative process conditions over extended campaign durations
• Inadequately validated cleaning procedures, leaving detectable residues of cleaning agents themselves as a novel impurity source
• Water system contamination, where nitrite can form through microbial nitrification of ammonia in poorly maintained water-for-injection or purified water systems, contributing to nitrosamine formation risk independent of any deliberately added reagent
• Airborne particulate and microbial contamination, particularly relevant for sterile and parenteral manufacturing environments where environmental monitoring programs are designed specifically to detect this source

Why this source matters:

This category is frequently underinvestigated precisely because it doesn't map to a specific reagent or starting material a batch record can point to directly — it requires facility-level and equipment-train-level investigation rather than simply reviewing a single batch's raw material certificates, which is why cleaning validation and equipment qualification records are so heavily scrutinised during regulatory inspections.

Source Category 5: Degradation During Storage and Shelf Life

Once manufacturing is complete, a drug substance or drug product doesn't become chemically inert — it remains subject to ongoing degradation processes throughout its shelf life.

What goes wrong at this stage:

• Oxidative degradation, particularly for molecules with electron-rich functional groups, alkenes, or phenolic structures susceptible to reaction with atmospheric or headspace oxygen
• Hydrolytic degradation, affecting ester, amide, and other hydrolytically labile functional groups under the influence of residual moisture
• Photolytic degradation, for light-sensitive molecules inadequately protected by packaging
• Thermal degradation, accelerated by inadequate storage temperature control during distribution and warehousing
• pH-dependent degradation, particularly relevant for liquid and semi-solid dosage forms where formulation buffer system breakdown or drift over time can shift local pH into a range favoring degradation
• Slow, cumulative nitrosamine formation, where trace nitrite and vulnerable amine functionality react gradually over extended shelf life, meaning nitrosamine levels are not necessarily fixed at the point of release

Why this source matters:

Degradation-related impurities are why regulatory guidance requires stability studies covering the full proposed shelf life under both long-term and accelerated conditions, rather than relying solely on release testing — a formulation that appears impurity-free at manufacture can develop a meaningfully different impurity profile by the time it reaches a patient.

Source Category 6: Packaging and Container-Closure Systems

A frequently overlooked impurity source is the packaging system itself — the materials in direct or indirect contact with the drug product throughout its shelf life.

What goes wrong at this stage:

• Leachables from container-closure components, where chemicals inherent to rubber stoppers, plastic containers, or coatings migrate into the drug product over time, particularly relevant for liquid and injectable formulations
• Extractables under exaggerated conditions, identified during packaging qualification studies as potential leachables under real-world storage conditions
• Printing inks and adhesives, some of which have been identified as sources of trace nitrite contributing to nitrosamine formation risk in blister-packaged solid oral dosage forms
• Nitrocellulose-containing packaging components, capable of generating nitrogen oxide gases in the packaging headspace that can react with susceptible amine-bearing drug substances through a pathway distinct from classical aqueous nitrosation

Why this source matters:

Because packaging-derived impurities often only manifest over time rather than being present at initial release, they are easy to miss without dedicated extractables and leachables studies — and by the time they're detected in a stability failure, root-cause investigation often has to reach back through a supply chain (packaging component supplier, ink or adhesive formulation) that the drug product manufacturer may not have scrutinized as closely as their API or excipient suppliers.

Visualizing the Complete Impurity Source Map

The diagram below maps how impurities can enter a drug substance or drug product at each stage of the product lifecycle, from the earliest starting materials through to patient administration.

This map underscores a point that a narrowly scoped investigation often misses: a single observed impurity could plausibly trace back to any of six structurally distinct points in the lifecycle, and the analytical evidence — not an assumption about where impurities "usually" come from — has to determine which one actually applies in a given case.

Key Differences: Impurity Source Categories at a Glance

Source Category	Stage of Lifecycle	Typical Impurity Type	Primary Control Lever
Starting materials	Pre-synthesis	Structurally related organic impurities	Supplier qualification, incoming testing
Reagents/solvents/catalysts	During synthesis	Residual solvents, elemental impurities, genotoxic impurities	Route design, reagent/solvent substitution
Synthetic intermediates	During synthesis	By-products, dimers, incomplete-reaction impurities	Process optimization, intermediate purification
Manufacturing equipment/facility	During manufacturing	Cross-contamination, elemental impurities	Cleaning validation, equipment qualification
Degradation (storage)	Post-manufacture	Oxidative, hydrolytic, photolytic degradants	Formulation design, storage conditions
Packaging/container-closure	Post-manufacture	Leachables, nitrosamine-contributing residues	Packaging qualification, extractables/leachables studies

Regulatory Framework — What Specifically Applies

Regulatory Document	Governs	Primary Source Category Addressed
ICH Q3A	Impurities in new drug substances	Process-related and degradation impurities in API
ICH Q3B	Impurities in new drug products	Degradation impurities in finished product
ICH Q3C	Residual solvents (class-based PDE limits)	Reagents/solvents
ICH Q3D	Elemental impurities	Reagents, catalysts, equipment
ICH Q3E (draft/emerging)	Extractables and leachables	Packaging/container-closure
ICH Q7	GMP for APIs	Starting materials, intermediates, equipment
ICH Q11	Development and manufacture of drug substances	Starting material justification
ICH M7	Genotoxic impurities	Reagents, intermediates, mutagenic alert structures
FDA Guidance: Control of Nitrosamine Impurities	Nitrosamine-specific risk assessment	Reagents, excipients, packaging, water systems
ICH Q1A(R2)	Stability testing	Degradation impurities across full shelf life

One practical point worth flagging: several of these guidance documents overlap deliberately at the boundaries between source categories — nitrosamine risk assessment, for instance, spans reagents, excipients, water systems, and packaging simultaneously, which is exactly why a nitrosamine investigation limited to "check the synthetic route" alone frequently misses the actual contributing source.

What Good Practice Actually Looks Like For process-related impurity sources:

• Build a full mass balance across the synthetic route during development, accounting for where each atom of starting material and reagent ends up, rather than only characterizing the final isolated product
• Qualify starting material and reagent suppliers against defined impurity specifications, not simply assay purity, since a supplier's material can pass a simple purity check while still carrying a specific structurally related impurity relevant to your process
• Apply cleaning validation with impurity-specific carryover limits for shared equipment, rather than generic visual cleanliness criteria alone
• Screen for elemental impurity risk per ICH Q3D at every stage where metal-containing catalysts, reagents, or equipment surfaces contact the process stream

For product-related (degradation) impurity sources:

• Conduct comprehensive forced degradation studies (acid, base, oxidative, thermal, photolytic) early in development to identify the molecule's genuine degradation pathways, not just the ones anticipated from structural analogy to related compounds
• Design stability protocols covering the full proposed shelf life under both long-term and accelerated conditions, with degradation-specific analytical methods validated to detect the relevant degradants at appropriate sensitivity
• Select packaging and storage conditions specifically informed by the degradation pathways identified during forced degradation and stability studies, rather than defaulting to standard packaging without confirmatory data
• Conduct extractables and leachables studies for any new packaging component or supplier change, since packaging-derived impurities are among the most commonly underinvestigated sources

For both:

• Maintain a structured, documented impurity source map (of the kind illustrated above) specific to each product, updated whenever the synthetic route, formulation, or packaging changes
• Train investigators to consider the full lifecycle source map during root-cause investigations, rather than defaulting to the most commonly implicated source without confirmatory evidence
• Reassess impurity source risk whenever any single element of the process changes — a new reagent supplier, a new equipment train, a new packaging component — since impurity risk assessments performed against a prior process configuration do not automatically remain valid

A Worked Example: Tracing an Unexpected Impurity to Its Actual Source

Consider a QC laboratory detecting a new, low-level impurity in a finished tablet during a routine stability pull at the 12-month timepoint, not present at release. The investigative discipline this article has outlined matters directly here.

The first question is whether the impurity is process-related or degradation-related — and its absence at release, combined with its appearance only after extended storage, strongly favors a degradation-related origin rather than a manufacturing-stage source. This immediately narrows the investigation away from synthetic route and toward Source Categories 5 and 6: storage-related degradation and packaging-derived contribution.

Mass spectrometric characterization of the new impurity reveals a mass consistent with an oxidative degradation product of the API's known reactive functional group — but before concluding the investigation, the team should also rule out a packaging-derived contribution, since certain packaging materials can catalyze or accelerate exactly this type of oxidative pathway through headspace oxygen exposure or trace metal leaching from container components. Confirmatory testing — comparing impurity growth rates across different packaging configurations tested during the original stability program — ultimately determines whether the root cause sits primarily in the molecule's inherent oxidative lability (a formulation-level fix, such as antioxidant addition) or in inadequate packaging protection (a packaging-level fix, such as switching to a more oxygen-impermeable blister material).

Notice that neither of these root causes would have been identified by defaulting to the common reflex of "check the API supplier" — the actual source, in this scenario, sits entirely downstream of drug substance manufacturing, in the interaction between the formulated product, its packaging, and its storage environment.

Common Pitfalls in Impurity Source Investigation Defaulting to the most commonly implicated source without confirmatory evidence. API supplier issues, while genuinely common, are not the only plausible source, and treating them as the default hypothesis without ruling out equipment, packaging, or degradation-related origins wastes investigation time and can delay identification of the actual root cause.
Assuming a compliant certificate of analysis rules out a raw material or API as a contributing source. A certificate of analysis reflects testing against a defined specification at a specific point in time; it does not guarantee the absence of every structurally plausible impurity, particularly for impurities the original specification wasn't designed to detect.
Treating equipment and facility-level sources as a last resort rather than a primary hypothesis. Because equipment-derived contamination doesn't map cleanly to a single batch record entry, investigators can systematically underweight this source category relative to how frequently it actually contributes to impurity findings.
Overlooking packaging as a potential source for impurities detected only during stability testing. An impurity absent at release but present at later stability timepoints should always prompt consideration of both degradation and packaging-derived contribution, rather than assuming degradation alone explains the entire pattern.
Failing to reassess the impurity source risk map after a process or supply chain change. A new reagent supplier, a new equipment train, or a new packaging component can each introduce a genuinely new impurity source that a prior, now-outdated risk assessment never considered.
Conclusion

The source of impurity in pharmaceutical chemistry is rarely a single point — it is a lifecycle-spanning landscape spanning starting materials, reagents and catalysts, synthetic intermediates, manufacturing equipment, storage-driven degradation, and packaging systems, each contributing a structurally and mechanistically distinct category of impurity risk. Treating impurity investigation as a search through this full landscape, rather than a reflexive check of the most commonly blamed source, is what separates an investigation that finds the actual root cause from one that closes with an unconfirmed, convenient explanation.

If a laboratory investigates every unexpected impurity by defaulting immediately to the API supplier, that laboratory is likely missing genuine contributions from equipment, packaging, and degradation pathways that a more systematic source map would have surfaced. If, conversely, an organisation maintains a current, product-specific impurity source map — spanning every stage from starting material to shelf life — root-cause investigations move faster, land on the correct answer more often, and generate the kind of defensible, evidence-based corrective action that regulators expect.

Whether you're building a comprehensive impurity source risk assessment, characterizing a newly identified process- or degradation-related impurity, or need well-documented reference standards to support root-cause investigation across your product's full lifecycle, analytical rigor at every stage is what makes the difference. Chemicea Pharmaceuticals supplies high-purity impurity reference standards, degradation products, and process-related impurities with complete characterization data (COA, NMR, MS, HPLC purity) to support impurity profiling, method validation, and regulatory submissions.

Frequently Asked Questions

Q1: What are the main sources of impurities in pharmaceutical substances?

The main sources of impurities in pharmaceutical substances span the entire product lifecycle: starting materials and raw materials, reagents/solvents/catalysts used during synthesis, synthetic intermediates and by-products, manufacturing equipment and facility environment, degradation occurring during storage and shelf life, and packaging or container-closure systems.

Q2: What is the difference between process-related and product-related impurities?

Process-related impurities arise during manufacturing and reflect something about how the material was made — unreacted starting material, synthetic by-products, reagent residues. Product-related (degradation) impurities arise after manufacturing is complete, through the drug substance or product's own chemical instability under heat, light, moisture, oxygen, or pH exposure during storage.

Q3: Can packaging materials really be a source of pharmaceutical impurities?

Yes. Container-closure components, printing inks, adhesives, and certain packaging materials have all been documented sources of leachable impurities, and in some cases have been specifically identified as contributors to nitrosamine formation risk through trace nitrite content or nitrogen oxide gas generation in packaging headspace.

Q4: Why is manufacturing equipment often an underinvestigated source of impurities?

Because equipment-derived contamination — from cross-contamination, corrosion, or inadequate cleaning — doesn't map cleanly to a single batch record entry the way a raw material or reagent does, investigators can systematically underweight this source relative to how frequently it actually contributes to impurity findings, making cleaning validation and equipment qualification records especially important during root-cause investigations.

Q5: How does ICH guidance categorize sources of impurities in pharmaceutical chemistry?

ICH Q3A and Q3B categorize impurities into organic impurities (process- and degradation-related), inorganic impurities (largely reagent-, catalyst-, and equipment-derived elemental impurities governed by ICH Q3D), and residual solvents (governed by ICH Q3C), while ICH Q7 and Q11 separately address starting material and intermediate-stage control expectations.

Q6: Why might an impurity appear during stability testing that wasn't present at release?

An impurity absent at release but appearing later typically indicates a degradation-related source — oxidative, hydrolytic, photolytic, or thermal instability of the drug substance or product — though packaging-derived contribution should also be considered, since some leachable or headspace-driven impurity formation pathways likewise develop gradually over storage time rather than being present immediately after manufacture.

Q7: What is the most effective way to prevent impurities from multiple sources simultaneously?

Rather than addressing each source category in isolation, effective prevention requires a product-specific, lifecycle-spanning impurity source risk assessment — covering starting materials, process chemistry, equipment, formulation, and packaging together — updated whenever any element of the supply chain, process, or packaging configuration changes.